Avoid equity investment due to extreme dilution risk and going concern issues. Monitor FDA decision on CTx-1301 in May 2026, but company likely needs emergency financing before then which could wipe out current shareholders.
Price Chart
Executive Summary
Cingulate Inc. filed an S-3/A amendment solely to update the auditor's consent from KPMG LLP. The filing does not modify the prospectus or indicate new securities issuance. However, the company's financials show a deteriorating position with declining cash, recurring losses, and reliance on dilutive financing, raising going concern doubts.
Key Facts
- S-3/A filing is purely administrative, updating KPMG's consent without changing the prospectus
- Company has $0 market cap and CINGW is likely delisted or non-trading
- Cash dropped from $12.2M to $6.1M in 9 months while net loss was $16.2M
- Relies on continuous dilutive financing (ATM, Lincoln Park, debt conversions)
- Management turmoil: CEO on administrative leave due to domestic battery charge
- FDA approval of lead drug CTx-1301 expected May 2026, but company may not survive until then
Financial Impact
Continuing cash burn of ~$1.8M/month with $6.1M remaining; needs $9M more to reach PDUFA date
Risk Factors
- Insufficient cash to continue operations beyond mid-2026
- Extreme shareholder dilution from continuous ATM and Lincoln Park financings
- Management instability with CEO on leave
- No revenue and complete dependence on FDA approval for survival
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (Primary) | 0001493152-26-012075 |
| Exhibit: ex23-1.htm | 0001493152-26-012075 |
| Document: 0001493152-26-012075-index-headers.html | 0001493152-26-012075 |
| Document: 0001493152-26-012075-index.html | 0001493152-26-012075 |
| Document: 0001493152-26-012075.txt | 0001493152-26-012075 |
| CONTEXT: 10-Q (2025-11-13) | 0001493152-25-022395 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 23d ago | 8-K | $4.75 | awaiting T+60 | — | $4.98 (+4.84%) |
Sep 22, 2026 4w ago | Institutional Cluster | $5.15 | awaiting T+60 | — | $4.98 (−3.21%) |
Aug 13, 2026 10w ago | 8-K | $4.99 | awaiting T+60 | — | $4.98 (−0.20%) |
Jul 14, 2026 14w ago | 8-K | $4.71 $4.87 | ▲ +3.40% | ▲ +0.02% | $4.98 (+5.73%) |
Jun 16, 2026 18w ago | 8-K | $4.74 $5.17 | ▲ +9.07% | ▲ +8.07% | $4.98 (+5.06%) |
Jun 8, 2026 19w ago | Insider Cluster | $4.65 $5.15 | ▲ +10.75% | ▲ +6.94% | $4.98 (+7.10%) |
Mar 25, 2026 30w ago | EFFECT | $6.36 $4.97 | ▼ −21.86% | ▼ −35.31% | $4.98 (−21.70%) |
Mar 23, 2026 31w ago | S-3/A | $6.93 $5.12 | ▲ +26.12% | ▲ +39.18% | $4.98 (+28.14%) |
Mar 18, 2026 31w ago | DEFA14A | $7.51 $4.93 | ▼ −34.35% | ▼ −48.70% | $4.98 (−33.69%) |
Mar 18, 2026 31w ago | 8-K | $8.04 $5.09 | ▼ −36.69% | ▼ −48.22% | $4.98 (−38.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers